Clinical Trials

Search Trials

For best results, use specific search terms. For example, instead of "brain tumor," try "glioblastoma." You can also contact the Clinical Trials Office at 312-695-1102 for assistance.

(xIRB NCI CIRB) Alliance A211801: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Eligibility Criteria Some of the eligibility criteria include: Participants must have a confirmed deleterious or likely deleterious BRCA 1 germline mutation (variant class 4 or 5) Age >= 25 years and =< 55 years at randomization No evidence of breast cancer by MRI or mammography (MG) and clinical breast examination within the last 6 months prior to randomization Negative pregnancy test at randomization for women of childbearing potential Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator Khan, Seema Ahsan Location(s) Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT04711109IRB number STU00217826 More Info Email Pulliam, Natalie E Phone +1 312 472 4767

(xIRB NCI CIRB) Alliance A211801: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation

This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.

Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.

Eligibility Criteria

Some of the eligibility criteria include:

Participants must have a confirmed deleterious or likely deleterious BRCA 1 germline mutation (variant class 4 or 5)
Age >= 25 years and =< 55 years at randomization
No evidence of breast cancer by MRI or mammography (MG) and clinical breast examination within the last 6 months prior to randomization
Negative pregnancy test at randomization for women of childbearing potential

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Principal Investigator

Khan, Seema Ahsan

Location(s)

Map it 201 E. Huron St.
Chicago, IL

ClinicalTrials.gov IdentifierNCT04711109IRB number STU00217826

More Info

Email Pulliam, Natalie E Phone +1 312 472 4767